A look at the progress of treating pancreatic cancer over the past 20 years

References

• Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
   PubMed Web of Science ®Google Scholar
• Lohr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol. 2006;3:236–237.
   PubMedGoogle Scholar
• Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5–27.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–1049.
   PubMed Web of Science ®Google Scholar
• Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40:1039–1047.
   PubMed Web of Science ®Google Scholar
• Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–348.
   PubMed Web of Science ®Google Scholar
• Turati F, Edefonti V, Bosetti C, et al. Family history of cancer and the risk of cancer: a network of case-control studies. Ann Oncol. 2013;24:2651–2656.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
   PubMed Web of Science ®Google Scholar
• Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010;170:791–802.
   PubMedGoogle Scholar
• Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:1880–1888.
   PubMed Web of Science ®Google Scholar
• Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076–2083.
   PubMed Web of Science ®Google Scholar
• Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433–1437.
   PubMed Web of Science ®Google Scholar
• Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23:374–382.
   PubMed Web of Science ®Google Scholar
• Malleo G, Vollmer CM Jr. Postpancreatectomy complications and management. Surg Clin North Am. 2016;96:1313–1336.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173–180.
   PubMed Web of Science ®Google Scholar
• Watson K. Carcinoma of ampulla of vater successful radical resection. Br J Surg. 1944;31:368–373.
   Google Scholar
• Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet. 1978;146:959–962.
   PubMedGoogle Scholar
• Whipple AO. Pancreaticoduodenectomy for Islet Carcinoma: a five-year follow-up. Ann Surg. 1945;121:847–852.
   PubMed Web of Science ®Google Scholar
• Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–1210, discussion 1210-1191.
   PubMed Web of Science ®Google Scholar
• Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg. 2005;242:540–544, discussion 544-547.
   PubMed Web of Science ®Google Scholar
• Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137.
   PubMed Web of Science ®Google Scholar
• Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–1344.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli S, Beger HG, Obertop H, et al. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg. 1999;16:337–345.
   PubMedGoogle Scholar
• Manabe T, Ohshio G, Baba N, et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer. 1989;64:1132–1137.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Jang J-Y, Kim S-W. Surgical resection of pancreatic head cancer: what is the optimal extent of surgery? Cancer Lett. 2016;382:259–265.
   PubMed Web of Science ®Google Scholar
• Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156:591–600.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028–1061.
   PubMed Web of Science ®Google Scholar
• Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–988.
   PubMed Web of Science ®Google Scholar
• Giovinazzo F, Turri G, Katz MH, et al. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103:179–191.
   PubMed Web of Science ®Google Scholar
• Yu XZ, Li J, Fu DL, et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol. 2014;40:371–378.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Z, Liu Y, et al. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36:884–891.
   PubMed Web of Science ®Google Scholar
• Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254:882–893.
   PubMed Web of Science ®Google Scholar
• Hartwig W, Hackert T, Hinz U, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250:81–87.
   PubMed Web of Science ®Google Scholar
• Mehrabi A, Hafezi M, Arvin J, et al. A systematic review and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and malignant lesions of the pancreas: it’s time to randomize. Surgery. 2015;157:45–55.
   PubMed Web of Science ®Google Scholar
• Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc. 1994;8:408–410.
   PubMed Web of Science ®Google Scholar
• Zureikat AH, Moser AJ, Boone BA, et al. 250 robotic pancreatic resections: safety and feasibility. Ann Surg. 2013;258:554–559, discussion 559-562.
   PubMed Web of Science ®Google Scholar
• Adam MA, Choudhury K, Dinan MA, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg. 2015;262:372–377.
   PubMed Web of Science ®Google Scholar
• Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, et al. Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg. 2014;218:129–139.
   PubMed Web of Science ®Google Scholar
• Traverso LW. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 2006;20(Suppl 2):S446–S449.
   PubMedGoogle Scholar
• Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater–results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993;29A:698–703.
   PubMed Web of Science ®Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–782, discussion 782-774.
   PubMed Web of Science ®Google Scholar
• Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621–633, discussion 633-626.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–1585.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–1081.
   PubMed Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–257.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820.
   PubMed Web of Science ®Google Scholar
• Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102:478–483.
   PubMed Web of Science ®Google Scholar
• Ko AH. Raising the bar for the adjuvant treatment of pancreatic cancer. Lancet. 2016;388:214–215.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–5518.
   PubMed Web of Science ®Google Scholar
• Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23:505–523.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Friess H, Buchler MW. Neoadjuvant therapy for pancreatic cancer. Br J Surg. 2007;94:261–262.
   PubMed Web of Science ®Google Scholar
• Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–512.
   PubMed Web of Science ®Google Scholar
• Fathi A, Christians KK, George B, et al. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015;6:418–429.
   PubMed Web of Science ®Google Scholar
• Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
   PubMed Web of Science ®Google Scholar
• Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–1339.
   PubMed Web of Science ®Google Scholar
• Hoffman JP, Weese JL, Solin LJ, et al. A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. Am Surg. 1993;59:772–780, discussion 780-771.
   PubMed Web of Science ®Google Scholar
• Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995;169:71–77, discussion 77-78.
   PubMed Web of Science ®Google Scholar
• Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–3502.
   PubMed Web of Science ®Google Scholar
• Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264:457–463.
   PubMed Web of Science ®Google Scholar
• Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191:7–16.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov N. Prospective randomized multicenter phase II trial to investigate intensified neoadjuvant chemotherapy in locally advanced pancreatic cancer. [cited 2017 Nov1]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02125136#contacts.
   Google Scholar
• ClinicalTrials.gov N. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: a prospective, randomized, controlled, phase II study of the AIO (working group for medical oncology from the german cancer society) pancreatic cancer group. [cited 2017 Nov 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02047513
   Google Scholar
• Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600.
   PubMed Web of Science ®Google Scholar
• Weinerman BH, MacCormick RE. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am J Clin Oncol. 1994;17:467–469.
   PubMed Web of Science ®Google Scholar
• Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–465.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–1315.
   PubMed Web of Science ®Google Scholar
• Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260–269.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Dobiasch S, Goerig NL, Fietkau R, et al. Essential role of radiation therapy for the treatment of pancreatic cancer: novel study concepts and established treatment recommendations. Strahlenther Onkol. 2017. https://doi.org/10.1007/s00066-017-1227-5.
   Web of Science ®Google Scholar
• Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–15.
   PubMed Web of Science ®Google Scholar